Mary Koshy, MD
Radiation Oncology · Bradenton, FLNPI 1609972967
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 33 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 12 manufacturers reported payments, led by Novocure Inc. at 43.1% of the total.
Across 33 payments — averaging $30.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novocure Inc.$429
- Myriad Genetic Laboratories, Inc.$122
- Sumitomo Pharma America, Inc.$117
- Blue Earth Diagnostics$61
- West Therapeutics Development, LLC$50
- Boston Scientific$45
- plus $172 from 6 others
What the payments were for
- Food & beverage$997100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novocure Inc. | 9 | $429 |
| Myriad Genetic Laboratories, Inc. | 3 | $122 |
| Sumitomo Pharma America, Inc. | 7 | $117 |
| Blue Earth Diagnostics | 2 | $61 |
| West Therapeutics Development, LLC | 3 | $50 |
| Boston Scientific | 1 | $45 |
| Fortovia Therapeutics, Inc. | 3 | $40 |
| Bioprotect Medical, Inc. | 1 | $36 |
| AstraZeneca | 1 | $28 |
| Novartis | 1 | $27 |
| Merck | 1 | $22 |
| Tactile Systems Technology Inc | 1 | $19 |
How this compares
$997 in reported general payments places this provider in the 55th percentile of 465 radiation oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SsdSilver Sulfadiazine | 90 | $3,359 |
| Sucralfate | 29 | $3,232 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 42 | $1,892 |
| Triamcinolone Acetonide | 168 | $950 |
| Ondansetron OdtOndansetron | 20 | $551 |
| Dexamethasone | 11 | $419 |
| Lidocaine Hcl ViscousLidocaine Hcl | 26 | $409 |
| Silver Sulfadiazine | 14 | $394 |
| Nystatin | 13 | $378 |
| Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc | 25 | $191 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Bradenton
- Shravan KandulaOrlando$444K
- Martin KeischMiami Shores$319K
- Marcio FagundesMiami$274K
- Evan ThomasWinter Park$209K
- Rupesh KotechaMiami$208K
- John SylvesterLakewood Ranch$205K
- Ravi ShridharOrlando$192K
- Alan BrownFort Myers$165K
- Akash NandaOrlando$165K
- Michael ChuongMiami$152K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.